Increasing emphasis on interprofessionalism and teamwork in healthcare renders psychologists’ collaborations critical and invites reexamination of psychologists’ roles related to medications. The Collaboration Level outlined by the American Psychological Association’s Ad Hoc Task Force is more achievable and in sync with health reform than prescription privileges (RxP). RxP remains controversial due to training and safety concerns, lacking support from health professionals, psychologists, and consumers. Differences in educational preparation of psychologists relative to prescribing professionals are discussed. Enactment of only three of 170 RxP initiatives reveals RxP to be a costly, ineffectual agenda. Alternatives (e.g., integrated care, collaboration, telehealth) increase access without risks associated with lesser medical knowledge. Concerns about RxP and the movement toward team-based care warrant reconsideration of the profession’s objectives regarding psychopharmacology.

Key words: integrative care, interprofessional, prescription privileges, prescriptive authority, psychologist, scope of practice. [Clin Psychol Sci Prac 20: 489–507, 2013]
opportunities to contribute substantively to patient care, but that lack the controversy of the agenda promoting prescription privileges for psychologists (RxP). We also review some of the history and concerns about psychologist prescribing, the relative limitations of the APA training model, and the impact of the pursuit of prescription privileges on the field, including the limited success and substantial costs of its legislative record.

**MEDICATION TRENDS**

Medications serve important roles in the arsenal of mental health treatments. According to the Substance Abuse and Mental Health Services Administration (SAMHSA, 2012), use of psychoactive medications increased by 96% from 127.2 million prescriptions filled in 1998 to 248.8 million prescriptions filled in 2007 in the United States. In 1998, the market for adult psychoactive medication expenditures was an estimated $10 billion. A decade later, psychoactive medication costs were estimated around $25 billion (SAMHSA, 2012). During this same period, Americans receiving medication-only treatment for mental health problems increased by 13.5%. By contrast, Americans getting combined psychotherapy and medication decreased from 40.0% to 32.1%, yielding a 13.3% decrease from 55.9% to 42.6% in the percentage engaging in psychotherapy as part of their treatment. These trends exist in the context of emerging evidence of the relative benefits of combined treatments (Cuijpers, Dekker, Hollon, & Andersson, 2009).

The locus of care in which psychopharmacological approaches are used for treating mental health disorders is broad. Up to two-thirds of individuals with mental health or substance use disorders or both are treated by physicians or other healthcare providers in the United States (Wang et al., 2005) and internationally (Wang et al., 2007). Many additional patients who are seen in primary care settings have subclinical mental health issues that may complicate diagnosis/treatment for physical health problems (Kessler et al., 2005). Despite the heterogeneous settings where patients obtain some type of care, nearly 70% of individuals with mental health conditions have been estimated to receive no treatment for their underlying mental health problems (Kessler et al., 2005). Of the minority who do receive mental health treatment, few are treated with evidence-based approaches that have been shown to be effective (Wang, Demler, & Kessler, 2002; Wang et al., 2007).

The number of prescriptions written by primary care physicians (PCPs) for psychotropic medications has increased dramatically since the mid-1990s (Lieberman, 2003). Physicians, physician assistants (PAs), and nurse practitioners, for example, wrote approximately 70% of all anxiolytic prescriptions, 68% of all antidepressant prescriptions, 57% of all prescriptions for stimulants, 43% of all antipsychotics, and 28% of mood stabilizers between August 2006 and July 2007 (DuBosar, 2009). Recent data question the efficacy of the most prescribed psychotropic medication, antidepressants, in treating all but severe symptoms (Fournier et al., 2010). There have been calls to rethink medications as a first-line form of treatment (Carlat, 2010) as concerns about whether medications might be partially responsible for worsening mental health outcomes (Whitaker, 2010) and for inducing various iatrogenic problems (Akiskal & Benazzi, 2006; Gentile, 2011) emerge.

Psychologists harbor a range of views of medications and what roles psychologists might best play vis-a-vis medications (Hayes, Walser, & Bach, 2002). Whereas most recognize the benefits medications confer for at least some of their patients, many are concerned about potential problems that can be associated with medications, such as adverse effects, risks of abuse, and trends toward overprescribing.

Although shortages of psychiatrists have long been recognized (Pardes & Pincus, 1983), as public acceptance of psychoactive medications has increased demand for psychopharmaceuticals, the limited access to psychiatrists has gained more attention. Psychologists have been remarkably silent about advocating for increased funding for training psychiatrists, which arguably would be the most direct solution to that problem. Instead, RxP proponents have identified access problems to psychiatrists as a main justification for RxP. Among psychologists, diverse views abound about how to ameliorate the problem of patients facing barriers to providers for psychoactive prescriptions. Advocates of RxP argue that securing prescription privileges provides psychologists direct roles, including the “power to not prescribe, or to help wean patients off medications” (Stambor, 2006, p. 30).
hand, RxP opponents contend that collaboration and interprofessional practice are safer and more effective approaches by which psychologists can work in conjunction with prescribers to effectively address patients’ health and mental health needs.

**COLLABORATION: A COMPELLING ALTERNATIVE TO RXP**

Whereas specialty mental health services are available from various mental health professionals (psychologists, marriage and family therapists, social workers, psychiatrists, etc.; Robiner, 2006) for individuals experiencing mental health problems, general medical settings present critical points of care within the healthcare system. Even patients who recognize their own mental health challenges may be reluctant to seek out specialty mental healthcare due to various concerns such as finances, insurance coverage, convenience, time, services location, referral inefficiencies, and stigma. This latter concern seems particularly true for ethnic minorities (Snowden & Pingitore, 2002; Vega, Kolody, Aguilar-Gaxiola, & Catalano, 1999). Providing mental health services in primary care settings facilitates patients’ acceptance of referrals for service, provides greater convenience of co-located services, builds on the already established trust with primary care providers, and increasingly takes advantage of the proximity of multiple types of providers working as a team (Frank, Bray, McDaniel, & Heldring, 2003).

Primary care settings are important loci of mental healthcare delivery in that there are a far greater number of physicians and “mid-level providers” (i.e., nurse practitioners and PAs) than other mental health prescribers (i.e., psychiatrists, prescribing psychologists) who provide basic mental health services. Nationally, there are an estimated 83,600 PAs (Bureau of Labor Statistics, 2010) and 105,700 nurse practitioners (Bureau of Labor Statistics, 2012), who by virtue of their sheer numbers are likely to have a far greater impact on meeting medication needs of populations than the relatively small number of psychologists seeking to prescribe could.

Primary care providers are more widely distributed than mental health professionals, who tend to cluster in urban and suburban areas, and consequently are more likely to treat patients in rural areas (Xierali et al., 2013). Thus, integrated care models that incorporate professionals who are skilled to coordinate a range of treatments, including psychological services, along with medical care by primary care providers, are promising avenues to improve mental healthcare access and outcomes (Butler et al., 2008).

Under the Patient Protection and Affordable Care Act (PPACA) and the Wellstone-Domenici Mental Health Parity and Addiction Equity Act (MHPAEA), more Americans will have insurance with mental health benefits covered commensurately with general medical benefits. The PPACA has many features intended to enhance and expand healthcare, including promotion of interprofessional care. Consequently, interest in interprofessional collaborative care has been burgeoning. Recently, several organizations have drafted guidelines to support curricula to help prepare future health and mental healthcare providers to engage in interprofessional collaboration (Institute of Medicine, 2013). The World Health Organization (WHO, 2010) defines collaborative practice in healthcare as occurring “when multiple health workers from different professional backgrounds provide comprehensive services by working with patients, their families, … and communities to deliver the highest quality of care across settings” (p. 13). Moreover, “a collaborative practice-ready health worker is someone who has learned how to work in an interprofessional team and is competent to do so” (p. 7).

The WHO considers interprofessional collaborations to be one of the most encouraging solutions regarding healthcare access and distribution problems and complex health-related challenges (APA, 2013; Health Resources and Services Administrator, 2010; WHO, 2010). Indeed, a shift is underway promoting interprofessional care in healthcare teams and the competencies clinicians need to provide team-based care (Interprofessional Education Collaborative Expert Panel, 2011). Models for providing integrated care (Heath, Wise, & Reynolds, 2013) and for preparing psychologists to function in integrated teams are emerging (Cubic, Mance, Turgesen, & Lamanna, 2012).

The Health Service Psychology Education Collaborative (2013) supported by the APA (2013) Blueprint for Health Service Psychology Education and Training delineated diverse competencies for health service psychology. These include the “interpersonal skills and
communication … to relate effectively with professionals from other disciplines and demonstrate competence in interprofessional collaborative practice” (p. 29) as well as the consultation competence to “provide consultative psychological services to patients and their families, other health care professionals, and systems related to health and behavior” (p. 31) and that they “are familiar with evidence-based consulting skills and methods” (p. 31).

Such developments arguably render the pursuit of RxP less compelling. Noncontroversial measures are gaining ascendancy, such as integrating psychologists in diverse healthcare settings, including primary care (American College of Neuropsychopharmacology, 2000; Bluestein & Cubic, 2009; Frank et al., 2003; Tovian, 2006). Deploying psychologists in primary care settings where they can provide interdisciplinary care in concert with prescribing health professionals (e.g., physicians, advanced practice nurses [APNs], PAs, consulting psychiatrists) who can manage medications in the context of patients’ other health care is not only less costly (Blount et al., 2007; Chomienne et al., 2011), but also obviates the risks of enabling prescriptive authority based on a training model considered controversial by various health professionals, including some psychologists, as will be discussed later in this article.

COLLABORATION AND PSYCHOPHARMACOLOGY TRAINING
Increasing psychologists’ education related to clinical psychopharmacology is generally accepted as having beneficial effects in enhancing how psychologists engage patients in regard to medications (Smyer et al., 1993). However, enhancing psychologists’ understanding about psychoactive medications has never necessitated pressing for RxP (Smyer et al., 1993). When the APA Ad Hoc Task Force on Psychopharmacology (Smyer et al., 1993) reviewed the desirability and feasibility of psychopharmacology prescription privileges for psychologists, it considered three potential levels of training for psychologists to consider. Level 2: Training for Collaborative Practice (a consultation–liaison model) was outlined by the APA Task Force (Smyer et al., 1993) but has been largely overlooked in favor of Level 3 training that provides a model for training psychologists to prescribe. Training for collaborative practice would enhance psychologists’ knowledge of psychopharmacology to work cooperatively with other health professionals without taking the controversial step of seeking independent prescribing. The collaborative level of training was more strongly favored by psychology graduate students (77%) as an option for their own training than prescribing (50%; Tatman, Peters, Greene, & Bongar, 1997). The Task Force recognized that few psychologists would seek to prescribe (Smyer et al., 1993). Nevertheless, it seems curious that APA developed an agenda seemingly exclusively promoting RxP while consistently ignoring the collaboration model (i.e., we are not aware of guidelines developed for collaboration related to prescribing by other disciplines or efforts to promote the collaboration model).

Disregarding the APA Task Force’s Collaborative Practice level seems particularly regrettable in that the APA (2007) Guidelines and Principles for Accreditation of Programs in Professional Psychology already mandate education and training that prepares psychologists to effectively consult with other health and mental healthcare providers so that graduates of all accredited programs presumably have basic skills in consultation, an important ingredient for successful collaboration.

Moreover, collaboration is much closer to what most psychologists actually do. According to the APA Center for Workforce Studies (CWS, 2009) Survey of Psychology Health Service Providers, the vast majority of psychologists collaborate with psychiatrists (89%), primary care physicians (79%), other medical specialists (50%), and nurse practitioners (51%), and over a quarter consult with PAs (27%). Moreover, about 90% of psychologists regularly discuss medications with physicians, and the majority provide information about medications to patients (APA CWS, 2009, Table 4a), an activity that enhances patient care but does not hinge on psychologists prescribing. These practice patterns of psychologists, in conjunction with the growing momentum of interprofessional team-based care, suggest that it is timely to take another, more serious look at Level 2 training outlined in the APA Task Force report (Smyer et al., 1993) as a potential means of achieving greater consensus in how the profession could most effectively establish collaborative roles for psychologists that capitalize on their clinical strengths. Our view on this is not unique. The
Canadian Psychological Association Task Force on Prescriptive Authority for Psychologists in Canada (2010) recently recommended that active collaborative practice with prescribing professions was “the optimal standard for contemporary psychological practices” (p. 27) rather than promoting RxP.

Psychologists’ contributions to collaborative care leverage their expertise and recognized competencies in psychological assessment, intervention, and consultation, and also present opportunities to undertake research that can enhance healthcare. Psychologists who wish to prescribe with training equivalent to other prescribers have always been free to explore more complete biomedical training available in other health professions (e.g., physicians, APNs, PAs). If they wish to be recognized as providing pharmacologic interventions that would indisputably be considered on par with other types of prescribing professionals, it is recommended that their education and training be equivalent to it, beginning with obtaining the undergraduate scientific training and ending with more intensive and broader clinical medical supervised experiences. For example, the Doctor of Nursing Practice degree, which is replacing the master’s-level nurse practitioner degree, requires a minimum of 1,000 supervised clinical hours.

Consumers, employers, and healthcare organizations, such as the Institute of Medicine, Committee on Crossing the Quality Chasm: Adaptation to Mental Health and Addictive Disorder (2006), are increasingly concerned with promoting quality care and preventing avoidable medical errors. In the current climate of increasing accountability within healthcare, it is imperative that providers be sufficiently trained to provide services that meet industry standards and that professionals practice within the contours of their competence.

**PSYCHOPHARMACOLOGY DEMONSTRATION PROJECT**

Two decades ago, the Department of Defense (DoD) undertook a pilot Psychopharmacology Demonstration Project (PDP) training 10 military psychologists to prescribe in a 2-year full-time program. When it was cancelled, the Government Accounting Office (GAO, 1997) report Need for More Prescribing Psychologists Is Not Adequately Justified concluded that “training psychologists to prescribe medication is not adequately justified because the [Military Health Services System] MHSS has no demonstrated need for them, the cost is substantial, and the benefits are uncertain” (p. 3). NBC News later presented its Golden Fleece Award to the project because of its poor cost-effectiveness (California Psychiatric Association, n.d.).

The final report of the Evaluation Panel of the PDP considered that

... a 2-year program—one year didactic, one year clinical practicum that includes at least a 6-month inpatient rotation—can transform licensed clinical psychologists into prescribing psychologists who can function effectively and safely in the military setting to expand the delivery of mental health treatment to a variety of patients and clients.

It also deemed the psychologist PDP graduates to be weaker medically than psychiatrists (American College of Neuropsychopharmacology, 2000). Rather than being assessed at the level of physicians, the PDP psychologists’ medical knowledge was assessed at a student level, which does not allow independent prescribing in any discipline in any jurisdiction. PDP graduates, themselves, recommended against shortcuts and reductions in required training. Most said an intensive full-time year of clinical experience, involving inpatients, was indispensible in addition to the comprehensive didactics. These features were not, however, included in the APA training model that was originally developed nor are they in the more recent iteration (APA, 2009). Similarly, they are not systematically incorporated in contemporary clinical psychopharmacology training programs.

**APA TRAINING MODEL AND CURRENT TRAINING**

In 1996, the APA adopted the prescription privileges (RxP) agenda as a matter of policy, justifying it partly on the basis of the PDP. It seeks to enable psychologists to prescribe independently, which is not currently the case in most jurisdictions for mid-level nonphysician prescribers. The APA also endorsed a psychopharmacology training model that was shorter, less intensive, and less organized than the PDP. Eligibility for undertaking the training to prescribe merely
requires psychologists to graduate from an accredited doctoral psychology program, be licensed, and practice as a “health services provider” psychologist (APA, 2009). Programs are required to have 400 contact hours covering eight domains and an unspecified length, breadth, or intensity of clinical supervised experience (APA, 2009). The APA (2009) recommendations for education and training for prescribing are available online.

Several postdoctoral master’s-level psychopharmacology training programs have opened, although none are associated with medical schools. Some are highly reliant on distance learning. RxP programs are designed for psychologists to continue to practice during the training. In contrast to the PDP, contemporary training for psychologists to prescribe is part-time and requires no inpatient training. For example, the Alliant International University (2012) program advertises on its website, “Earn your degree at home on weekends.” New Mexico State University (2011) acknowledges on its website that this truncated schedule may shape course coverage of material: “We will cover as many drug classes as we can in the time allotted.”

Strikingly, the programs do not meet the APA’s (2007) own accreditation criteria that are in effect for psychology graduate, internship, and postdoctoral training. That is, they are not required to be carefully scrutinized externally as are other levels of clinical training in psychology and as are other prescribing disciplines’ training programs. Even the APA’s (2009) revised psychopharmacology training model describes training that is narrower and less rigorous than the PDP training.

Although RxP proponents have acknowledged that the PDP training was more consistent with core medical training models in terms of didactics focused on biochemistry, pathophysiology, and clinical medicine than current clinical psychopharmacology training programs (McGrath, 2010), they typically dismiss the relevance of this training and contend that supplementary hours in postdoctoral training in psychopharmacology address these deficiencies in training. The absence of rigorous testing of psychologists’ foundational biomedical and scientific deficits precludes understanding their effects. We question how sufficiently foundational deficiencies can be overcome and the advanced knowledge and clinical experience for prescribing can be gained in relatively abbreviated and distance learning training programs. We remain skeptical of the proposition that psychologists might be able to master more quickly the complex nexus of knowledge and skills for prescribing and managing medications than learners in other disciplines.

Some might argue that the relatively cursory training for RxP currently available is a form of “bait and switch” from the more robust PDP training that was used to justify RxP originally. The relatively more condensed nature of existing training seems likely to render it inferior to that provided in the PDP as well as relative to the training of other prescribers. It also raises questions about the breadth, depth, and quality of such training. For example, how can consumers and policymakers be ensured what other prescribers learn in longer time frames, but that is excluded from an abbreviated curriculum, is not important in maximizing clinical outcomes? After all, when medications enter the human body, they do not just affect emotional regulation within the brain, but also have broader physical effects across organ systems (Stuart & Heiby, 2007) that may interact with other classes of medication.

DIFFERENCES BETWEEN PSYCHOLOGY AND (OTHER) PRESCRIBING DISCIPLINES
Graduate training in psychology differs substantively from other health professions from the start. It requires neither undergraduate prerequisites nor graduate coursework in basic scientific and biomedical domains (e.g., biology, chemistry, organic chemistry, biochemistry, physiology, and pathophysiology). Such courses are generally recognized as foundational to understanding biological and biochemical processes inherent in health and illness, how the human body responds to medications, and how interactions among systems and medications affect people (Heiby, 2010).

RxP proponents concede that among nonphysician health professionals, “…psychology has the core curriculum with probably the least overlap with traditional medical curricula” (Fox et al., 2009, p. 258). The training paradigms are so different that only 7% of psychology graduate students are estimated (Tatman et al., 1997) to have completed biology and chemistry undergraduate coursework considered adequate for prescribing by APA’s own Ad Hoc Task Force of experts.
when considering possible levels of psychopharmacology training (Smyer et al., 1993).

In contrast to other health professions, to gain admittance to current RxP training programs, students are *neither* required to complete scientific foundational coursework *before* enrolling nor to demonstrate competence in those domains through standardized admissions examinations (e.g., MCAT). The Psychopharmacology Examination for Psychologists (PEP), a 150-item multiple-choice test that is the only required testing for psychologists to prescribe, contrasts with the more comprehensive, sequential testing such as the United States Medical Licensing Examinations (USMLE Step 1, 2 [CK and CS], and 3). Without more extensive objective testing following rigorous coursework, it is highly speculative to presume that the training psychologists receive could be equivalent to that of physicians or other prescribers, or be sufficient for managing medications, especially in people with complex comorbid conditions, such as older adults. Without broader and in-depth physical science education, biomedical knowledge, and experiential medical training, psychologist prescribing arguably constitutes an experiment for which there has been no objective, systematic, or comprehensive evaluation.

Proponents of RxP summarily dismiss the importance of training that aligns with a medical school model requiring students to have a strong foundation in the physical sciences (McGrath, 2010; Muse & McGrath, 2010). This contention contrasts with the view of many (78.6%) psychologists, who believe that to prescribe, psychologists should have equivalent training (Baird, 2007). RxP proponents argue that because nonphysician prescribers (e.g., nurse practitioners) provide quality care that results in health outcomes similar to that provided by physicians (e.g., comparable control of asthma, diabetes, and hypertension; health services utilization; patient satisfaction; Munding et al., 2000), even though they did not attend medical school, psychologists’ training need not be equivalent to physicians either. However, as noted by Heiby (2010), all other nonphysician prescribers typically *do* have more extensive scientific (i.e., physical sciences) training at the undergraduate level than psychologists (Figure 1). Moreover, other prescribers and nonprescribing disciplines have broader and more intensive clinical medical training at the graduate level than is afforded by clinical psychopharmacology training for psychologists.

The absence of scientific and medical training for psychologists in the undergraduate and graduate education sequence leads to questions about how abbreviated training *after* the education to become a psychologist could be adequate to enable prescribing at levels of knowledge and competence commensurate with other prescribers (Table 1; Robiner et al., 2002, 2003). The absence of any undergraduate premedical scientific prerequisites to enter training to prescribe violates recommendations of the APA’s own experts on the APA (1992) Ad Hoc Task Force on Psychopharmacology, who stipulated that

...retraining of practicing psychologists for prescription privileges would need to carefully consider selection criteria, focusing on those psychologists with the necessary science background.... It would require students to have undergraduate science training similar to that required of other health service providers (e.g., nurses, pharmacists, allied health professionals, dentists, and/or physicians). It would also require a postdoctoral period of supervised clinical experience. (p. 400)

The potential for insufficient medical preparation is compounded by the reality that many psychologists train in settings outside of the healthcare system (e.g., schools, counseling centers, prisons, social service agencies). For the APA to unilaterally determine that the basic scientific foundation required in other prescribing professions is unnecessary for psychologists suggests an underestimation of the complexity of the human body and drugs’ effects on it. It also could signify inadequate respect of the contributions of those scientific disciplines to the understanding of the mechanisms and effects of medications whose elements are omitted. This calculation to ignore scientific foundations assumedly derives from an objective to provide brief, affordable training so that more practicing psychologists might complete it. Yet, even with this shortcut, relatively small numbers of psychologists currently prescribe. Concerns about the abbreviated nature of the training fuel opposition to RxP, in various other health professions as well as among psychologists.
Figure 1. College basic science prerequisite courses for admission to health science programs.

Note. Multiply credits by 10 for estimated hours of instruction. These data were derived by a 2013 survey of admission requirements to the largest programs in New Jersey (e.g., Farleigh Dickinson University, University of Medicine and Dentistry of New Jersey, Rutgers University). Although there were no physical or health sciences prerequisites for entry into the PhD programs in Clinical Psychology, both the FDU and Rutgers curriculum included one course in biopsychology or behavioral neuroscience. The MS Clinical Psychopharmacology program is an example of a program intended to train psychologists to prescribe and requires considerably less than programs for other prescribers and nonprescribers.

Table 1. Knowledge base and clinical proficiencies required for prescribing

<table>
<thead>
<tr>
<th>Psychopathology and Psychological Issues</th>
<th>Medical Status Prior to Prescribing</th>
<th>Response to Treatments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary psychiatric conditions</td>
<td>Comorbid medical conditions</td>
<td>Knowledge of adverse reactions</td>
</tr>
<tr>
<td>Comorbid psychiatric conditions</td>
<td>Contraindications</td>
<td>1. Side effects</td>
</tr>
<tr>
<td>Prevalence and course of psychiatric conditions</td>
<td>Medical effects of concurrent treatments</td>
<td>2. Toxic effects</td>
</tr>
<tr>
<td></td>
<td>1. Drug interactions</td>
<td>Ability to recognize, diagnose, and treat adverse reactions</td>
</tr>
<tr>
<td></td>
<td>2. Other treatments (e.g., dialysis, plasmapheresis)</td>
<td>Ability to differentiate between physical and psychiatric effects of psychoactive agents and concurrent medications</td>
</tr>
<tr>
<td>Knowledge of nonpharmacologic treatment options</td>
<td>Long-term effects of medications</td>
<td>Other issues related to monitoring, titrating, or discontinuing prescribed medications</td>
</tr>
<tr>
<td></td>
<td>History of medication use</td>
<td></td>
</tr>
</tbody>
</table>

Note. The education of psychologists typically addresses column 1, but neglects columns 2 and 3. Based on Robiner et al. (2002).
Whereas the interests and competencies of psychologists and psychiatrists overlap, there are differences in training and experience. As Steven Kingsbury, MD, PhD, a psychologist who later became a psychiatrist, observed:

"Studying the effects of medications on the kidney, the heart, and so forth is important for the use of many medications. Managing these effects is often crucial and has more to do with biochemistry and physiology than with psychology. I was surprised to discover how little about medication use has to do with psychological principles and how much of it is just medical." (Kingsbury, 1992, p. 5)

He also contrasted the intensity and exposure to patients in his training in the two professions:

"In my first month of residency training in psychiatry at a psychiatry emergency service I believe I saw more patients individually than in my entire graduate training [i.e., in psychology]." (Kingsbury, 1987, p. 155)

Although anecdotal, these concerns and differences are not trivial. They are likely representative of the gaps between the medical preparation of psychologists and that of other prescribers.

**PSYCHOLOGISTS’ PERSPECTIVES ON PSYCHOLOGIST PRESCRIBING**

The RxP movement developed within psychology as some psychologists sought to expand their scope of practice and, thereby, their clinical and economic opportunities. It did not develop in response to entreaties from other health professions, public health officials, or consumers and was not supported by academic psychologists (Lavoie & Barone, 2006). Although many psychologists support RxP in principle, unlike other professions with prescriptive authority, RxP remains controversial among psychologists, particularly when details of legislative proposals are considered (Hayes & Heiby, 1998; Heiby, 2002a, 2010; Robiner et al., 2002, 2003; Wagner, 2002; Walters, 2001).

Within psychology, opposing groups have included the Society for a Science of Clinical Psychology (2001); American Association of Applied and Preventive Psychology (1998); Committee Against Medicalizing Psychology (Pollitt, 2003); and most recently, Psychologists Opposed to Prescription Privileges for Psychologists (POPPP; see www.poppp.org).

In contrast to prescribing professions, most psychologists do not intend to prescribe (Baird, 2007; Campbell, Kearns, & Patchin, 2006), a trend that prevents RxP from becoming a viable strategy for counteracting the shortage of psychiatrists, for which it is often touted as a remedy. Even RxP advocates acknowledge that “…only a minority of practitioners has evinced interest in seeking the ability to prescribe” (Fox et al., 2009, p. 257).

Some psychologists seem to support RxP in theory, although practically speaking express no desire to pursue training or practice; others oppose it (Walters, 2001). Interestingly, psychologists’ understanding of the details of prescribing training issues may be limited, so it is difficult to determine what individual psychologists think they support if they do endorse the RxP agenda. Baird’s (2007) survey revealed that most (78.6%) psychologists believed that to prescribe, psychologists should receive training commensurate with other nonphysician prescribers. As noted above, APA’s current training model does not meet that objective in terms of foundational knowledge, intensity, or breadth of clinical experience, nor oversight through national accreditation.

**PROFESSIONALS’ AND CONSUMERS’ VIEWS OF PSYCHOLOGIST PRESCRIBING**

Although there is consensus on the need for mental health services in the military, and more broadly throughout society, it is unclear whether training psychologists to prescribe is an effective means of addressing these needs. Instead, societal needs might be better served by investing resources toward ensuring all mental health consumers have improved access to psychological services, especially evidence-based therapies, which are typically first-line treatments for a host of common mental health issues. For example, after reviewing the published literature on antidepressants and other therapies, the National Health Service in England adopted cognitive behavioral therapy as a first-line treatment for mild and moderate depression and has invested £400 million over the next four years to increase patient access to psychotherapy to treat depression and anxiety disorders, including plans to train up to 6,000 therapists in cognitive behavioral therapy.
The RxP agenda is opposed by other health professionals, and it undermines interprofessional relations (Bush, 2002). The American Psychiatric Association and the American Medical Association have consistently lobbied against it, although conceding they would have no quarrel with psychologists obtaining prescriptive authority as mid-level medical practitioners if their training was equivalent to other mid-level practitioners (i.e., nurse practitioners, PAs). Opposition to RxP notably extends far beyond organized medicine. The International Society of Psychiatric-Mental Health Nurses (2001) contends that nurses have an “ethical responsibility” to oppose RxP.

Moreover, consumers are wary of RxP. The National Alliance on Mental Illness (NAMI), the largest mental health advocacy and support organization, does not support RxP. NAMI’s executive director noted that because “these [psychoactive agents] are serious drugs with serious side effects … we feel strongly that [prescribing] should be handled by someone with medical training” (Andrews, 2011).

Although RxP advocates claim that psychologists prescribe without problems, there is little, if any, systematic, empirical evidence for the desirability, feasibility, safety, and cost-effectiveness of RxP (Lavoie & Barone, 2006). The unknown consequences of relative deficits in knowledge, experience, and competence associated with abbreviated training raise cautions (American College of Neuropsychopharmacology, 2000; Butler et al., 2008; Robiner et al., 2003). As a public health issue, the fundamental concerns about RxP are patient safety and the quality of care that psychologists could deliver in prescribing relative to other prescribing professions. Gaps in psychologists’ training to manage medications, relative to that of other prescribers, presumably persist even after a psychologist might complete training conforming to the APA model.

**POTENTIAL ADVERSE EFFECTS AND LIMITATIONS OF PSYCHOACTIVE MEDICATIONS**

Psychoactive medications are commonly used in the treatment of anxiety, depression, insomnia, psychosis, and other conditions and have become more accepted by consumers. Nevertheless, they are powerful drugs with risks for significant adverse effects that require monitoring by qualified health professionals who can assess their effects. This includes being prepared to discern whether symptoms are due to the prescribed medications, to other medications, to interactions between psychoactive medications and other medications, or whether they might indicate other medical conditions for which treatment is needed; these are not conditions psychologists are trained to assess or treat.

The potential for harm from psychoactive medications is considerable. The U.S. Food and Drug Administration (FDA) requires black box warnings about risks of using antipsychotics with the elderly due to increased risk of death and other adverse effects (cardiac toxicity, stroke, infection, hyperglycemia) and for antidepressants in adolescents and young adults due to possible increased risk of suicidal ideation. Selective serotonin reuptake inhibitors (SSRIs) can cause hematological disorders, including gastrointestinal and retinal hemorrhage and other serious problems. One study found the odds of mortality were 3.22 times higher for those using anxiolytic and hypnotic medications in the past month (Belleville, 2010). A study of reports to the FDA from 1998 to 2005 revealed threefold increases in serious morbidity and mortality associated with adverse drug events (ADEs), with disproportionate incidence in the elderly (Moore, Cohen, & Furberg, 2007). Two antidepressants, paroxetine and venlafaxine, were among the agents with the most frequent, serious outcomes. Antipsychotics (clozapine, risperidone, olanzapine) and paroxetine were among drugs with the most frequently suspected associated deaths.

Complications associated with psychoactive medications include cardiac arrhythmias, insulin resistance, obesity, movement disorders, neuroleptic malignant syndrome, serotonin syndrome, sexual dysfunctions, and adverse drug event due to drug interactions (Stuart & Heiby, 2007). Antidepressants and mood stabilizers account for an estimated 20,000 ADEs requiring treatment in emergency departments (EDs; Budnitz et al., 2006). Antipsychotics and benzodiazepines, respectively, accounted for 13,635 and 9,299 ADEs resulting in ED visits. The medical risks and adverse effects associated with these agents, and the costs incurred with care to address them, warrant that prescribers have full
understanding of human pathophysiology, morbidity, pharmacology, and the formulary beyond psychopharmacology (Stuart & Heiby, 2007). Unfortunately, the truncated focus of psychopharmacology training programs for psychologists raises questions about whether the curriculum is sufficiently broad and intensive to address patients’ overall functioning.

The rationale for RxP also is questioned as evidence mounts that antidepressants are used to treat mild to moderate conditions for which they may perform no better than placebo (Fournier et al., 2010), potentially resulting in overmedication. It is unclear how knowledgeable and discerning potential prescribing psychologists are about both the adverse effects and the bounds of therapeutic effects. Research suggests that some claims made to clinicians and the public through medical journals and direct-to-consumer advertisement may be misleading and lack sufficient empirical support (i.e., well-controlled and executed studies) and government oversight (Spielmans, Thieges, Dent, & Greenberg, 2008), making it essential that prescribers be sufficiently educated to understand for themselves the science underlying drugs’ action.

CONTROVERSIAL ISSUES ASSOCIATED WITH RXP

Despite such concerns, the APA Practice Organization (APAPO) and its affiliates have mounted campaigns lobbying state legislatures to authorize RxP to psychologists who obtain postgraduate training based on the APA model. Proponents contend that allowing psychologists to prescribe would expand patient access to medications. They posit that expanding psychologists’ scope of practice could enhance services for the underserved, such as in rural areas. Whereas access problems do exist and warrant remedy, claims about how well RxP would solve those problems deserve closer scrutiny and have been disputed (Lavoie & Baron, 2006; Pollitt, 2003; Robiner et al., 2002).

For example, an article in the American Journal of Law & Medicine argues that RxP advocates disingenuously mislead legislators to grant psychologists prescriptive authority (Pollitt, 2003). The reality is that psychologists and psychiatrists have similar demographic distribution patterns, tending to practice in urban and suburban areas, rather than rural areas (Figure 2). Consequently, RxP is not likely to meaningfully attenuate rural prescriber workforce shortages. As noted earlier, developing interprofessional collaborations with PCPs is more likely to improve access to psychopharmacological services.

Furthermore, mental health access issues in obtaining psychotherapeutic interventions and psychological assessments in both rural and urban areas may be more challenging than accessing pharmacotherapy (Campbell et al., 2006; Westra, Eastwood, Bouffard, & Gerritsen, 2006). One study revealed that most family practitioners thought there were psychological and psychiatric services available in their communities for collaboration and consultation and that they would be reluctant to refer patients to psychologists for pharmacological management (Bell, Diggan, & McKenna, 1995). Other approaches, such as telepsychiatry, offer the potential to compensate for some psychiatric workforce shortages (O’Reilly et al., 2007). The shortage of psychiatrists neither logically nor prudently leads to the conclusion that psychologists should prescribe. As members of the “de facto” mental health system, primary care physicians and mid-level providers can prescribe sufficiently well to meet many patients’ needs. Enhancing the systems and intensifying the training that underlies primary care providers’ mental healthcare delivery has the potential to further improve their prescribing quality, as does enhancing psychologists’ capacity to function effectively in healthcare teams to coordinate care that is based on the interplay of the respective clinical strengths of their disciplines.

THE RXP LEGISLATIVE RECORD

APA has allocated considerable resources to promoting RxP. By 2001, APA had spent more than $1 million on the RxP legislative agenda (DeLeon, 2002). The APAPO has provided grants to state psychological associations to support RxP lobbying. The full amount that has been spent by the APA and groups of RxP supporters is unknown. The authors’ requests to the APAPO for financial records related to RxP went unanswered. Conversely, the costs to counter legislative initiatives for RxP are not known. Were RxP not a battleground, such lobbying efforts alternatively could be used collaboratively to promote a broader consensual agenda to advance mental healthcare and education within and across disciplines.

The campaign to promote RxP has yielded modest success, which in behavioral terms might be characterized
as intermittent reinforcement, suggesting that the RxP agenda is not likely to extinguish readily. Guam was the first jurisdiction to pass RxP legislation in 1998. Whereas RxP proponents hail this as a historical milestone in their movement, and widely cite it to justify promoting legislation in other areas, it seems misleading in that none of the 14 psychologists licensed in Guam when this article was written are authorized to prescribe. To our knowledge, this absence of an actual impact of Guam’s legislation on patient care in Guam or on psychologists’ activities there has never been acknowledged by RxP proponents as they have routinely cited it when advocating for RxP in discussions with their colleagues and legislators.

New Mexico and Louisiana are the only states that have enacted RxP legislation, in 2002 and 2004, respectively. As of the writing of this article (i.e., about a decade after passage of enabling legislation), only 26 psychologists were authorized to prescribe in New Mexico (another nine are considered conditional) and only 71 in Louisiana. These numbers represent small percentages of the licensed psychologists by psychology boards in New Mexico (3.7%; 705) and Louisiana (10.7%; 665), and a trivial fraction (0.1%) of the
estimated 92,227 clinically trained psychologists nationally (SAMHSA, 2012). A review of the medical and nursing boards’ annual reports of those states reveals that these numbers are also much smaller than the number of APNs and PAs who can prescribe in New Mexico (1,286 APNs; 688 PAs) and Louisiana (3,939 APNs; 712 PAs), respectively. The influence of psychologist prescribers in addressing the medication needs in these states relative to other physician and nonphysician prescribers would appear minimal based on the numbers alone, further raising questions about the actual impact of promoting RxP.

Prescribing psychologists’ impact on the delivery of mental health services in those jurisdictions that authorize prescriptive authority has not been systematically assessed. No large-scale, objective evaluations of the impact of psychologists prescribing, or the potential problems associated with it, have been undertaken or published. To the authors’ knowledge, none are planned. The bounds of the “mission creep” seeking to broaden psychology’s purview to prescribing (Heesacker, 2005) are not known. Some proponents propose that psychologists’ formulary should extend beyond psychopharmacology, on which the RxP movement was originally focused, and to which psychopharmacology training is principally dedicated, to other medications such as for weight loss, sleep disorders, chronic pain, and nicotine addiction (Earles, James, & Folen, 2006).

Despite the expansive vision of RxP proponents, the superficial appeal of their rhetoric, and the disproportionate attention they have garnered within the profession, the RxP legislative record has been lackluster. Fox et al. (2009) estimated that at least 88 RxP legislative initiatives had been introduced in 21 jurisdictions. Using a somewhat different methodology that counts specific bills, we estimate that 170 initiatives to authorize psychologist prescribing have been introduced in about half of the U.S. states and two territories. Figure 3 presents a map of RxP initiatives introduced between 1995 and 2012. Of these bills, 167 (98.2%) failed. No states have enacted RxP legislation since 2004. Some bills have failed to garner adequate support in legislatures. Two met gubernatorial veto. In 2013, additional bills in New Jersey and Illinois were defeated but are not included in this analysis because they technically may still be introduced in 2013. Although a precise, cumulative tally of the lobbying and other resources APA has marshaled to promote RxP is not available, the paltry record of enactment of RxP legislation reveals that the RxP agenda has been costly for the profession. We believe the record deserves psychologists’ close attention. It raises critical questions as to whether in lobbying for the still controversial RxP agenda professional organizations are exercising prudent stewardship of their resources (e.g., dues revenues).

**OTHER EFFECTS OF PROMOTING THE RXP AGENDA**

Pursuing RxP arguably has diverted the profession’s attention and resources from dealing with other matters, such as lobbying for additional funding levels for psychological services, graduate education, scientific research, and preparing for medical homes and accountable care organizations. It has also distracted from focusing on the development of clinical practice guidelines and policies that might better meet the needs of the public and practitioners, and from addressing other pressing professional matters (e.g., workforce, internship imbalance, equity, health reform and healthcare redesign, licensure mobility).

Moreover, psychologists’ pursuit of RxP undermines interprofessional relations with disciplines that oppose RxP and is divisive among psychologists. Since just “a small minority of psychologists” has ever been expected to seek prescription privileges (Smyer et al., 1993), APA’s and APAPO’s allocations of resources to promote RxP have disproportionally served relatively few psychologists, rather than the broader profession. These priorities and the attendant stewardship of resources diminishes support for the APA among psychologists who view the RxP as a misguided agenda and as incompatible with their values, and/or irrelevant to their aspirations, activities, and needs.

Over a decade ago, Heiby (2002b) proposed a moratorium on legislation enabling RxP due to the absence of sound outcome data related to the training model and the RxP movement’s divisiveness. To the authors’ knowledge, only one published study has sought to evaluate the impact, utility, and safety of prescribing psychologists in practice. Shearer, Harmon, Seavey, and Tiu (2012) recently surveyed 47 primary care
providers and residents who worked closely with a single (i.e., n = 1) prescribing psychologist in a family medicine clinic in an Army medical center. Although they concluded their study provided evidence that prescribing psychologists “practice safely and effectively” (Shearer et al., 2012, p. 428), this conclusion based on essentially anecdotal data seems premature.

It is unclear to what degree Level 2 (i.e., collaboration) trained psychologists, or other psychologists, would receive similar positive ratings by providing consultation, but not prescribing, and what additional services they could provide if not prescribing. Additionally, as Shearer et al. (2012) note, the clear limitations in their methodology and sample limit their ability to answer questions about psychologist prescribing. For example, they did not ask whether it would have been preferable to have a psychiatrist provide the psychopharmacological consultation (in person or via telehealth) or what concerns they would have about referring ill and complex patients. They did not assess what medical phenomena related to prescribing psychologists might miss. Needed are more comprehensive investigations of prescribing psychologists (e.g., in New Mexico and Louisiana) outside the structured setting of military facilities that yield reliable and valid data regarding patient outcomes (i.e., safety and effectiveness) and prescribing patterns in independent (i.e., not military) or less structured settings. Additionally, objective, independent data that evaluate error rates in psychologist prescribing and psychologists’ detection rates of adverse effects of medications and that move beyond anecdotal impressions are essential to addressing questions of whether and where prescribing psychologists might provide quality care. Similarly, assessments of whether RxP meaningfully affects access to psychoactive medications in underserved areas are warranted.

The history of RxP provides an important case study for psychologists’ role in promoting or supporting legislation. It clarifies that unlike other APA policies and guidelines, the outcome of legislative initiatives is not determined by the preferences of APA, its council, divisions, committees, task forces, and members, but rather by a much broader group of stakeholders including governmental authorities, policy groups, other health professionals and social scientists, consumers, as well as dissenting psychologists. In promoting legislation, APA should fully consider the risks, benefits, and total capital needed to be expended to successfully pursue its legislative priorities such that it wisely manages its resources. The authors recom-
mend that APA’s legislative agenda and efforts focus on the goals and professional activities that benefit its overall membership, rather than supporting RxP, which would appear to only benefit a small, if vocal, group of psychologists.

Psychologists contribute substantively to the public health through the provision of diverse mental health and broader health services, research, and education and deserve fuller recognition for the importance of their work. The opportunities for psychologists to flourish in the dawning era of team-based healthcare are before us. Psychologists’ success in this new era will be determined by the quality of their services, their outcomes, and their capacity to collaborate effectively. We believe the public and the profession are best served by having psychologists provide those health services for which they are trained rigorously (e.g., assessment, psychotherapy, consultation, supervision, and research). In many cases, psychologists are indeed the most extensively trained among all health and mental health professionals for rendering them. As interprofessional team-based care revolutionizes the delivery of healthcare, refocusing the profession’s psychopharmacology agenda to better prepare psychologists to collaborate with prescribers seems likely to be a more prudent, impactful, and promising strategy that would be fully in sync with broader healthcare trends than continuing its undistinguished record in the pursuit of RxP.

NOTE 1. Because prescribing psychologists in Louisiana are now licensed by the Louisiana State Board of Medical Examiners (LSBME) but still have the option of being duly licensed by the Louisiana State Board of Examiners of Psychologists (LSBEP) as well, we could not determine what the total number of psychologists is in the state. Hence, the figure cited, 665, is based on the LSBEP number data and may not include all of the psychologists. As such, the 10.7% estimated percentage of all Louisiana psychologists who can prescribe is probably an overestimate of the actual proportion of prescribing psychologists. Unfortunately, the LSBEP does not track the number of psychologists licensed with both boards.

REFERENCES


Muse, M., & McGrath, R. E. (2010). Training comparisons among three professions prescribing psychoactive...


Received September 26, 2013; accepted September 30, 2013.